ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
NCT01110486
Completed
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with carboplatin or docetaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2013
Locations: Site Reference ID/Investigator# 26525, Chicago, Illinois +1 locations
Conditions: Advanced Solid Tumors
Register for Updates
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
NCT00883675
Completed
The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2013
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire +11 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
NCT00095875
Completed
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. It is not yet known which regimen of chemotherapy and radiation therapy is most effective in treating head and neck cancer. PURPOSE: Randomized phase III trial to compare the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2013
Locations: Rebecca and John Moores UCSD Cancer Center, La Jolla, California +14 locations
Conditions: Head and Neck Cancer
Register for Updates
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
NCT00255762
Completed
This phase II trial is studying how well giving carboplatin and paclitaxel together with bevacizumab works in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to gr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2013
Locations: North Central Cancer Treatment Group, Rochester, Minnesota
Conditions: Recurrent Melanoma, Stage IV Melanoma
Register for Updates
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
NCT00600821
Completed
To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2013
Locations: Pfizer Investigational Site, Baton Rouge, Louisiana +43 locations
Conditions: Non-Small-Cell Lung Carcinoma, Adenocarcinoma
Register for Updates
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
NCT00828841
Completed
This study is testing the investigational drug, cetuximab, in combination with different chemotherapy drugs for lung cancer. The aim of the study is to determine which of the drug combinations looks most promising and should be tested further. The study will also look at what side effects may occur.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2013
Locations: Not set, Anniston, Alabama +83 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT00058461
Terminated
This phase II trial is studying how well rituximab together with ifosfamide, carboplatin, and etoposide works in treating young patients with recurrent or refractory non-Hodgkin's lymphoma or acute lymphoblastic leukemia. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances t... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
10/07/2013
Locations: Children's Oncology Group, Arcadia, California
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, L3 Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma
Register for Updates
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
NCT00147537
Completed
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2013
Locations: Pfizer Investigational Site, Tucson, Arizona +30 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
NCT00002616
Unknown
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Peripheral stem cell transplantation combined with biological therapy may be an effective treatment for breast cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 with filgrastim to stimulate cell production in treating patients with stage IIIB, stage IV, metastatic, or recurrent breast cancer who will undergo peripheral stem cell transplantation.
Gender:
ALL
Ages:
64 years and below
Trial Updated:
09/19/2013
Locations: University of Illinois at Chicago Health Sciences Center, Chicago, Illinois
Conditions: Breast Cancer
Register for Updates
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
NCT00413283
Completed
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2013
Locations: Research Site, Glendale, Arizona +112 locations
Conditions: Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
Register for Updates
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
NCT00118053
Terminated
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving trastuzumab together with docetaxel and carboplatin may kill more tu... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/17/2013
Locations: Central Jersey Oncology Center, PA - East Brunswick, East Brunswick, New Jersey +8 locations
Conditions: Breast Cancer
Register for Updates
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
NCT00938652
Completed
The goal of this study was to determine the effect on overall survival and progression free survival by adding iniparib (BSI-201/SAR240550) to the combination of gemcitabine/carboplatin in adult patients with triple negative breast cancer (estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative). Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the poly (A... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/13/2013
Locations: Research Site, Birmingham, Alabama +101 locations
Conditions: Breast Cancer
Register for Updates